NYSE:CVM

CEL-SCI (CVM) Stock Forecast, Price & News

$1.22

+0.03 (+2.53%)

(As of 12:38 PM ET)

Compare

Today's Range: $1.19
▼
$1.22
50-Day Range: $1.17
▼
$2.46
52-Week Range: $1.08
▼
$3.68

Volume: 57,561 shs
Average Volume: 213,943 shs
Market Capitalization: $57.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

CEL-SCI MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 736.8% Upside
$10.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.69) to ($0.48) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

876th out of 975 stocks

Biological Products, Except Diagnostic Industry

149th out of 162 stocks

3.5

Analyst's Opinion

Consensus Rating
CEL-SCI has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, CEL-SCI has a forecasted upside of 736.8% from its current price of $1.20.
Amount of Analyst Coverage
CEL-SCI has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for CVM.

0.0

Dividend Strength

Dividend Yield
CEL-SCI does not currently pay a dividend.
Dividend Growth
CEL-SCI does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CVM.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 3 news articles for CEL-SCI this week, compared to 0 articles on an average week.
Search Interest
7 people have searched for CVM on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added CEL-SCI to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CEL-SCI insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.24% of the stock of CEL-SCI is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.46% of the stock of CEL-SCI is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for CEL-SCI are expected to grow in the coming year, from ($0.69) to ($0.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CEL-SCI is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CEL-SCI is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CEL-SCI has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CEL-SCI (NYSE:CVM) Stock

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

CVM Price History

30 days | 90 days | 365 days | Advanced Chart

CVM Stock News Headlines

September 27, 2023 | americanbankingnews.com

CEL-SCI (NYSE:CVM) & Abcam (NASDAQ:ABCM) Financial Survey

September 26, 2023 | finance.yahoo.com

CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer

September 28, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

September 23, 2023 | americanbankingnews.com

Contrasting CEL-SCI (NYSE:CVM) and Outlook Therapeutics (NASDAQ:OTLK)

September 20, 2023 | americanbankingnews.com

CEL-SCI (NYSE:CVM) Trading Up 8.3%

August 11, 2023 | finance.yahoo.com

CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results

July 31, 2023 | finance.yahoo.com

CVM: Model Revisions

July 20, 2023 | finance.yahoo.com

CEL-SCI Announces Closing of Public Offering

September 28, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

July 19, 2023 | msn.com

CEL-SCI stock dips on pricing $5 million capital raise via stock offering

July 18, 2023 | msn.com

Cel-Sci (NYSE:CVM) Plummets on $5M Stock Offering

July 18, 2023 | benzinga.com

Why CEL-SCI (CVM) Shares Are Down 20%

July 18, 2023 | marketwatch.com

CEL-SCI Shares Slide Premarket After Public Offering Priced >CVM

July 17, 2023 | finance.yahoo.com

CEL-SCI Announces Pricing of Public Offering

July 17, 2023 | businesswire.com

CEL-SCI Announces Proposed Public Offering of Common Stock

July 17, 2023 | msn.com

CEL-SCI shares tumble on stock offering plans

July 14, 2023 | seekingalpha.com

CEL-SCI receives FDA feedback on lead asset Multikine

July 14, 2023 | finance.yahoo.com

CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer

July 12, 2023 | msn.com

EF Hutton Reiterates Cel-Sci (CVM) Buy Recommendation

July 12, 2023 | benzinga.com

EF Hutton Reiterates Buy on CEL-SCI, Maintains $10 Price Target

June 22, 2023 | benzinga.com

CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed

June 1, 2023 | nz.finance.yahoo.com

CVM - CEL-SCI Corporation

May 16, 2023 | finance.yahoo.com

CVM: Health Canada Conditional Approval

May 15, 2023 | finance.yahoo.com

Why CEL-SCI Shares Are Shooting Higher Today

May 12, 2023 | businesswire.com

CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results

April 27, 2023 | finance.yahoo.com

CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock

April 19, 2023 | stockhouse.com

CEL-SCI to Pursue Canada's Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer

See More Headlines

Receive CVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.

CVM Company Calendar

Last Earnings: 8/11/2023
Today: 9/28/2023
Fiscal Year End: 9/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:CVM
CUSIP: N/A
CIK: 725363
Web: cel-sci.com
Phone: 703-506-9460
Fax: 703-506-9471
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +740.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,700,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -141.00%
Return on Assets: -79.78%

Debt

Debt-to-Equity Ratio: 0.70
Current Ratio: 1.46
Quick Ratio: 1.06

Sales & Book Value

Annual Sales: $560,000.00
Price / Sales: 100.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.74 per share
Price / Book: 1.61

Miscellaneous

Outstanding Shares: 47,260,000
Free Float: 39,585,000
Market Cap: $56.24 million
Optionable: Optionable
Beta: 1.31

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Geert R. Kersten Esq. (Age 64)
Chief Exec. & Financial Officer, Treasurer and Director
Comp: $681.99k

Ms. Patricia B. Prichep (Age 72)
Sr. VP of Operations & Corp. Sec.
Comp: $286.03k

Dr. Eyal Talor Ph.D. (Age 67)
Chief Scientific Officer
Comp: $340.59k

Dr. Daniel H. Zimmerman Ph.D. (Age 82)
Sr. VP of Research & Cellular Immunology
Comp: $262.86k

Mr. John Cipriano (Age 81)
Sr. VP of Regulatory Affairs
Comp: $239.1k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CVM Stock - Frequently Asked Questions

Should I buy or sell CEL-SCI stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CEL-SCI in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CVM shares.
View CVM analyst ratings or view top-rated stocks.
What is CEL-SCI's stock price forecast for 2023?: 1 equities research analysts have issued 12 month target prices for CEL-SCI's stock. Their CVM share price forecasts range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 740.3% from the stock's current price.
View analysts price targets for CVM or view top-rated stocks among Wall Street analysts.
How have CVM shares performed in 2023?: CEL-SCI's stock was trading at $2.35 at the beginning of 2023. Since then, CVM stock has decreased by 49.4% and is now trading at $1.19.
View the best growth stocks for 2023 here.
How were CEL-SCI's earnings last quarter?: CEL-SCI Co. (NYSE:CVM) released its quarterly earnings data on Friday, August, 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02.
When did CEL-SCI's stock split?: CEL-SCI shares reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is CEL-SCI's stock symbol?: CEL-SCI trades on the New York Stock Exchange (NYSE) under the ticker symbol "CVM."
Who are CEL-SCI's major shareholders?: CEL-SCI's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.60%), D.A. Davidson & CO. (1.12%), Geode Capital Management LLC (0.90%), State Street Corp (0.36%), Simplex Trading LLC (0.00%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Bruno Jean-Marie Baillavoine, Eyal Talor, Geert R Kersten, John Cipriano, Peter R Young and Robert Eugene Watson.
View institutional ownership trends.
How do I buy shares of CEL-SCI?: Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is CEL-SCI's stock price today?: One share of CVM stock can currently be purchased for approximately $1.19.
How much money does CEL-SCI make?: CEL-SCI (NYSE:CVM) has a market capitalization of $56.24 million and generates $560,000.00 in revenue each year. The company earns $-36,700,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.
How can I contact CEL-SCI?: CEL-SCI's mailing address is 8229 Boone Boulevard, Suite 802, Vienna, VA 22182, United States. The official website for the company is cel-sci.com. The company can be reached via phone at 703-506-9460, via email at gdewindt@cel-sci.com, or via fax at 703-506-9471.

This page (NYSE:CVM) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CEL-SCI (CVM) Stock Forecast, Price & News

CEL-SCI MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About CEL-SCI (NYSE:CVM) Stock

CVM Price History

CVM Stock News Headlines

CVM Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

CVM Stock - Frequently Asked Questions

Overall MarketRank^™